Washington, DC (December 17, 2002) – The Biotechnology Industry Organization (BIO) is pleased to announce the First Annual Industrial Biotechnology Analyst and Investor Briefing to be held January 23, 2003 in New York City at the National Academy of Sciences. Credentialed members of the media may register onsite. This inaugural event for the financial community will highlight industrial biotechnology and demonstrate the wide applications of biotechnology beyond healthcare. The briefing is a half-day educational event, entitled “The Third Wave of Biotechnology,” and will focus solely on industrial biotechnology and emphasize the progress this sector has made and the growing industrial enzyme, bioenergy and biobased materials markets, which are rapidly transforming multiple products and industries.
“The Third Wave of Biotechnology creates a much needed forum to highlight the progress of the industrial side of biotechnology, which is often neglected by traditional investor forums,” said Brent Erickson, vice president of BIO’s industrial and environmental section. “This event will demonstrate the environmental benefits industrial biotechnology is bringing to society and the substantial potential for market growth in this area.”
The briefing will include plenary panel discussions by industry leaders and practitioners, addressing the profound impact industrial biotechnology has had on our way of life. Moderator led sessions will focus on specific issues of interest, including: Industrial Biotechnology Supporting the Needs of an Advancing Society; Technology Drivers of the Industry; Biotechnology. . .It’s Not Just Healthcare!; and Driving a $100 Billion Market, Perspectives on the Industry.
“This conference provides the opportunity for investors to learn about this exciting sector that is beginning to come into its own,” commented Jean-Jacques Bienaimé, CEO of Genencor International. “Building greater awareness of industrial biotechnology and highlighting innovations in this area will highlight the unlimited possibilities that lie ahead.”
BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products
# # #